Author | Edgardo S. Santos, MD, FACP, FCCP | OncLive

Author | Edgardo S. Santos, MD, FACP, FCCP

Articles

Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC

May 30, 2020

Video

Edgardo S. Santos, MD, FACP, FCCP, discusses the FDA approval of the combination of ramucirumab and erlotinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.

x